Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States.

During the 2009 influenza pandemic, the Centers for Disease Control and Prevention provided antiviral susceptibility testing for patients infected with suspected drug-resistant viruses. Specimens from 72 patients admitted to an intensive care unit or with a severe immunocompromising condition, who failed to clinically improve after oseltamivir treatment, were accepted for testing. Respiratory specimens were tested for the presence of the oseltamivir resistance-conferring H275Y substitution in the neuraminidase (NA) by pyrosequencing. Virus isolates propagated in MDCK cells were tested in phenotypic NA inhibition (NI) assays using licensed NA inhibitors (NAIs), zanamivir and oseltamivir, and investigational NAIs, peramivir and laninamivir. Conventional sequencing and plaque purification were conducted on a subset of viruses. Pyrosequencing data were obtained for 87 specimens collected from 58 of the 72 (81%) patients. Of all patients, 27 (38%) had at least one specimen in which H275Y was detected. Analysis of sequential samples from nine patients revealed intra-treatment emergence of H275Y variant and a shift from wildtype-to-H275Y in quasispecies during oseltamivir therapy. A shift in the H275Y proportion was observed as a result of virus propagation in MDCK cells. Overall, the NI method was less sensitive than pyrosequencing in detecting the presence of H275Y variants in virus isolates. Using the NI method, isolates containing H275Y variant at⩾50% exhibited resistance to oseltamivir and peramivir, but retained full susceptibility to zanamivir. H275Y viruses recovered from two patients had an additional substitution I223K or I223R that conferred a 38-52- and 33-97-fold enhancement in oseltamivir- and peramivir-resistance, respectively. These viruses also showed decreased susceptibility to zanamivir and laninamivir. These data suggest that pyrosequencing is a powerful tool for timely detection of NAI resistant viruses and that NI assays are needed for comprehensive testing to detect novel resistance substitutions.

[1]  L. Gubareva,et al.  Characteristics of Patients with Oseltamivir-Resistant Pandemic (H1N1) 2009, United States , 2011, Emerging infectious diseases.

[2]  L. Gubareva,et al.  Detection of E119V and E119I Mutations in Influenza A (H3N2) Viruses Isolated from an Immunocompromised Patient: Challenges in Diagnosis of Oseltamivir Resistance , 2010, Antimicrobial Agents and Chemotherapy.

[3]  Ji-Rong Yang,et al.  Early findings of oseltamivir-resistant pandemic (H1N1) 2009 influenza A viruses in Taiwan. , 2010, Antiviral research.

[4]  M. Zambon,et al.  Rapid Quantitation of Neuraminidase Inhibitor Drug Resistance in Influenza virus Quasispecies , 2008, Antiviral therapy.

[5]  Ha T. Nguyen,et al.  Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  T. Mehta,et al.  Detection of Oseltamivir Resistance during Treatment of 2009 H1N1 Influenza Virus Infection in Immunocompromised Patients: Utility of Cycle Threshold Values of Qualitative Real-Time Reverse Transcriptase PCR , 2010, Journal of Clinical Microbiology.

[7]  Arjun Srinivasan,et al.  Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients--North Carolina, 2009. , 2011, The Journal of infectious diseases.

[8]  Frederick Hayden,et al.  Developing new antiviral agents for influenza treatment: what does the future hold? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Ha T. Nguyen,et al.  Comprehensive assessment of 2009 Pandemic Influenza a (H1N1) Virus Drug Susceptibility in vitro , 2010, Antiviral therapy.

[10]  D. Operario,et al.  Highly Sensitive and Quantitative Detection of the H 274 Y Oseltamivir Resistance Mutation in Seasonal A / H 1 N 1 Influenza Virus , 2010 .

[11]  Ha T. Nguyen,et al.  Neuraminidase Inhibitor Susceptibility Testing in Human Influenza Viruses: A Laboratory Surveillance Perspective , 2010, Viruses.

[12]  Ha T. Nguyen,et al.  Assessment of Pandemic and Seasonal Influenza A (H1N1) Virus Susceptibility to Neuraminidase Inhibitors in Three Enzyme Activity Inhibition Assays , 2010, Antimicrobial Agents and Chemotherapy.

[13]  R. Garten,et al.  Detection of Molecular Markers of Drug Resistance in 2009 Pandemic Influenza A (H1N1) Viruses by Pyrosequencing , 2009, Antimicrobial Agents and Chemotherapy.

[14]  Update: influenza activity--United States, 2010-11 season, and composition of the 2011-12 influenza vaccine. , 2011, MMWR. Morbidity and mortality weekly report.

[15]  Lynnette Brammer,et al.  Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. , 2009, JAMA.

[16]  N. Saksena,et al.  Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections. , 2010, Antiviral research.

[17]  D. Operario,et al.  Highly Sensitive and Quantitative Detection of the H274Y Oseltamivir Resistance Mutation in Seasonal A/H1N1 Influenza Virus , 2010, Journal of Clinical Microbiology.

[18]  J. van de Kassteele,et al.  Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season , 2009, Emerging infectious diseases.

[19]  Michael Shaw,et al.  Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. , 2010, The New England journal of medicine.

[20]  P. Simmonds,et al.  The emergence of oseltamivir-resistant pandemic influenza A (H1N1) 2009 virus amongst hospitalised immunocompromised patients in Scotland, November-December, 2009. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.